Site provided by Valneva USA, Inc.

INDICATION & USAGE

IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.

Vaccination with IXIARO may not protect all individuals.  Immunocompromised individuals may have a diminished immune response to IXIARO. Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.

Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO).

Please see full Prescribing Information.

    

INDICATION & USAGE

IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.

Vaccination with IXIARO may not protect all individuals.  Immunocompromised individuals may have a diminished immune response to IXIARO. Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.

Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO).

Please see full Prescribing Information.

    

 

 

Learn about the devastating consequences of JE through first-person  accounts, as real patients and families affected by JE share their stories. 

JE News

This section contains practical news articles about Japanese encephalitis (JE) for healthcare professionals.

News about JE

10/22/19 – Vietnam – “Boy comatose wakes up after 2 years– A 15-year-old boy in northern Hoa Binh Province, who was in a coma for two years due to Japanese encephalitis, has regained consciousness.

10/19/19 – “Taiwan: 99th local dengue case, Additional Japanese encephalitis case confirmed

10/2/2019 – India – “Teenager dies of Japanese encephalitis

9/12/19 – India – “Japanese Encephalitis kills 154 in Assam, the highest since 2014

9/1/19 – India – “Sharp decline in Acute Encephalitis Syndrome, Japanese Encephalitis deaths: Uttar Pradesh government

8/28/19 – “More than devastating’—patient experiences and neurological sequelae of Japanese Encephalitis

8/19/19 – Philippines – “Bayambang girl dies of Japanese encephalitis

8/16/19 – Philippines – “Japanese encephalitis takes the life of Pangasinan teen

08/4/19 – Hong Kong – “Japanese encephalitis case probed

7/20/19 – India – “9 Japanese encephalitis cases reported in Nagaland

7/19/19 – CDC Publishes Updated Recommendations for Valneva’s Japanese Encephalitis Vaccine IXIARO® – ACIP Guidelines Recommend Vaccination for All Longer-Term U.S. Travelers to JE-Endemic Countries; Shorter-Term Travelers Should Also Consider Vaccination.

7/17/19 – Malaysia – “Japanese Encephalitis in Malaysia – 15 cases and 3 deaths

7/15/19 – India – “11 Cases of Japanese Encephalitis Detected in Arunachal Pradesh

7/10/19 – Taiwan – “Taiwan: Japanese encephalitis reported in Taichung City

7/7/19 – India – “India: Japanese encephalitis deaths near 50 in Assam 

7/2/19 – Taiwan – “Taiwan: More dengue, Japanese encephalitis and enterovirus

6/26/19 – Taiwan – “Taiwan reports 3 additional Japanese encephalitis cases including 1 fatality

5/22/19 – Vietnam – “HN (Hanoi) reports first Japanese encephalitis case of the year

5/2/19 – “Perspective – Japanese encephalitis vaccine for travelers: risk-benefit Reconsidered – Bradley A Connor, Davidson H Hamer, Phyllis Kozarsky, Elaine Jong, Scott B Halstead, Jay Keystone, Maria D Mileno, Richard Dawood, Bonnie Rogers, William B Bunn, Japanese encephalitis vaccine for travelers: risk-benefit reconsidered, Journal of Travel Medicine, Volume 26, Issue 5, 2019,.

3/19/19 – Philippines – “Baguio officials urge public to get vaccinated: Measles and Japanese encephalitis

5/26/14 – Journal of Travel Medicine – “A Case Series of Three US Adults with Japanese Encephalitis, 2010-2012

Indication & Usage

IXIARO is a vaccine indicated for the prevention of disease caused by JE virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction (e.g., anaphylaxis) after a previous dose of IXIARO, any other Japanese encephalitis vaccine, or any component of IXIARO, including protamine sulfate ─ a compound known to cause hypersensitivity reactions in some individuals ─ is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO might be considered.

Vaccination with IXIARO may not protect all individuals. Immunocompromised individuals may have a diminished immune response to IXIARO.  Syncope can occur in association with administration of injectable vaccines, including IXIARO. Procedures should be in place to prevent injury from falling and manage syncopal reactions.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, myalgia, and injection site pain and tenderness in adults.

Healthcare practitioners are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  Healthcare practitioners are also encouraged to report inadvertent use in pregnant women to Valneva at 844-349-4276 (8443-IXIARO).

Please see full Prescribing Information.

Valneva USA, Inc.
910 Clopper Road, Suite 160S
Gaithersburg, MD 20878, USA

Customer Service
+1 866 223 7118

Medical Information
+1 844 349 4276
     (8443-IXIARO)

This website is intended for US-based healthcare professionals.

US-IXI-2100059 | Copyright © 2021 Valneva USA, Inc. All Rights Reserved